Skip to main content

Ambrx Biopharma, Inc.

AMAMDelisted Mar 7, 2024
Industry
Biological Products, (No Diagnostic Substances)
SEC CIK
0001990550

Ambrx Biopharma, Inc. was delisted on Mar 7, 2024; its insiders filed their last Form 4 on Mar 7, 2024; 68 institutions reported holding it in 13F filings for Q4 2023, worth $912.7M in total; no superinvestor held it.

Q4 2022 vs. Q3 2022

How the institutions holding Ambrx Biopharma, Inc. changed between Q3 2022 and Q4 2022.

All holders in Q4 2022All holders in Q3 2022

13F holders of AMAM: Q3 2022 compared with Q4 2022
MeasureQ3 2022Q4 2022Change
Holders1618+2
Shares16.7M17.9M+1.27M (+7.6%)
Value$18.0M$40.7M+$22.7M (+126.2%)

New holders (6)

Institutions that held Ambrx Biopharma, Inc. at the end of Q4 2022 but not at the end of Q3 2022.

Institutions new to AMAM in Q4 2022
InstitutionSharesValue% of portfolio
Darwin Global Management, Ltd.7,584,489$17.2M10.72%
Alpine Global Management, LLC46,723$106.0K0.04%
National Asset Management, Inc.20,000$45.4K0.00%
Cubist Systematic Strategies, LLC17,905$40.6K0.00%
Simplex Trading, LLC11,045$25.0K0.00%
Cutler Group LP436$00.00%

Sold out (4)

Institutions that held Ambrx Biopharma, Inc. at the end of Q3 2022 and filed for Q4 2022 without it.

Institutions that sold out of AMAM in Q4 2022
InstitutionShares, Q3 2022Value, Q3 2022
BlackRock Inc.2,851,433$3.08M
Suvretta Capital Management, LLC1,491,832$1.61M
Royal Bank of Canada42,453$46.0K
Tudor Investment Corp Et Al16,315$18.0K